Document Detail

Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension.
MedLine Citation:
PMID:  17012628     Owner:  NLM     Status:  MEDLINE    
Addition of inhaled iloprost to bosentan may have beneficial effects in patients with idiopathic pulmonary arterial hypertension (IPAH). A multicentre, open, randomised, controlled trial was performed to assess the safety and efficacy of inhaled iloprost in patients with IPAH who had already been treated with bosentan. The trial was terminated early after a futility analysis predicted failure with respect to the predetermined sample size. At that time, 40 patients were randomised to receive either bosentan alone (control group) or bosentan plus inhaled iloprost (combination group) for a 12-week period. The primary end-point, change in 6-min walking distance, was not met (mean changes +1 m and -9 m in the control and combination group, respectively). These results may have been skewed by three outliers in the iloprost group who presented with severe clinical worsening. None of the secondary end-points including functional class, peak oxygen uptake, and time to clinical worsening differed significantly between groups. The current study failed to show a positive effect of adding inhaled iloprost to bosentan in idiopathic pulmonary arterial hypertension patients. Further studies involving larger sample sizes and long-term follow-up are needed to determine the efficacy of adding inhaled iloprost to bosentan in patients with idiopathic pulmonary arterial hypertension.
M M Hoeper; H Leuchte; M Halank; H Wilkens; F J Meyer; H J Seyfarth; R Wensel; F Ripken; H Bremer; S Kluge; G Hoeffken; J Behr
Related Documents :
18174638 - Novel phosphodiesterase-5 inhibitors: current indications and future directions.
2252188 - Life-threatening complications during anaesthesia in a patient with a ventriculo-atrial...
11478818 - Haemodynamic, invasive and echocardiographic monitoring in the hypertensive parturient.
1340438 - Vasodilators in persistent pulmonary hypertension of the newborn: a need for optimal ap...
1752898 - A case of congenital hypoplasia of the right external iliac artery.
8203578 - Beta-adrenergic mechanisms attenuated hypoxic pulmonary vasoconstriction during systemi...
Publication Detail:
Type:  Clinical Trial, Phase IV; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The European respiratory journal     Volume:  28     ISSN:  0903-1936     ISO Abbreviation:  Eur. Respir. J.     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-10-02     Completed Date:  2007-02-01     Revised Date:  2013-06-18    
Medline Journal Info:
Nlm Unique ID:  8803460     Medline TA:  Eur Respir J     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  691-4     Citation Subset:  IM    
Hannover Medical School, Dept of Respiratory Medicine, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Inhalation
Antihypertensive Agents / therapeutic use*
Drug Therapy, Combination
Exercise Test
Hypertension, Pulmonary / drug therapy*
Iloprost / administration & dosage,  adverse effects,  therapeutic use*
Middle Aged
Sulfonamides / therapeutic use*
Vasodilator Agents / administration & dosage,  adverse effects,  therapeutic use*
Reg. No./Substance:
0/Antihypertensive Agents; 0/Sulfonamides; 0/Vasodilator Agents; 78919-13-8/Iloprost; Q326023R30/bosentan
Comment In:
Eur Respir J. 2006 Oct;28(4):683-6   [PMID:  17012626 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Short polybasic peptide sequences are potent inhibitors of PC5/6 and PC7: Use of positional scanning...
Next Document:  Parental smoking increases exhaled nitric oxide in young children.